LOGIN  |  REGISTER
Cue Biopharma

Information on the total number of voting rights and shares

December 29, 2022 | Last Trade: US$7.86 0.09 1.16

Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants.

  •  Share capital: EUR 4,440,069.16 
  •  Total number of securities carrying voting rights: 25,846,279 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 25,846,279 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  55 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  450,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 460,500 securities carrying voting rights (all ordinary shares); and
    •  1,350,750 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,350,750 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).  

For further information, please contact:

Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 749 1494

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page